Red Flags Detected

  • Going Concern (worsened) — Runway extended from April 2025 to June 2026 via equity raises, but accumulated deficit grew $15M to $68.6M and net loss widened to $14.9M.
NASDAQ: BIAFW bioAffinity Technologies, Inc. 10-K

bioAffinity enrolls first patient in pivotal lung cancer trial; revenue falls 34% on pathology exit

Filed March 16, 2026 · Period ending December 31, 2025 · Compared to 10-K Mar 31, 2025 · ~2 min read

5 material changes detected in this filing.

Create a free account to read the full summary — it takes 30 seconds.

Partner

Trade BIAFW commission-free

Open an account, get a free stock.

Sign up

Investing involves risk. Free stock terms apply.

View original filing on SEC.gov View full financials on EDGAR ↗

Generated by AI · Jun 4, 2026 11:51 PM